Drugs / TWB-103
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03624023 | Dec 2019 → Jul 2021 | ulcer of lower limbs | Transwell Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT02737748 | Jul 2017 → May 2021 | — | Transwell Biotech Co., Ltd. | Completed | Mixed |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TWB-103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02737748 ↗ |
| Route | Topical | “TWB-103 will be applied to the target ulcer wound once a week by the investigator” NCT03624023 ↗ |